ban ner6
ban ner4
ban ner3

product

Detection Kits & Sample-prep

  • Cervical Cancer

    Cervical Cancer

    This product is used for in vitro qualitative detection of hypermethylation of the gene PCDHGB7 in cervical specimens.
    Learn More >>
  • Endometrial Cancer

    Endometrial Cancer

    This product is used for in vitro qualitative detection of hypermethylation of the gene PCDHGB7 in cervical specimens.
    Learn More >>
  • Urothelial Cancer

    Urothelial Cancer

    This product is used for in vitro qualitative detection of hypermethylation of the Urothelial Carcinoma(UC) gene in urothelial specimens.
    Learn More >>
  • Pan-cancer

    Pan-cancer

    The whole-cancer detection is the plasma ctDNA methylation test products that are developed by TAGMe, which requires at least 3ml of whole blood to
    Learn More >>
more >>

about us

About Epiprobe

Shanghai Epiprobe Biotechnology Co., Ltd.

what we do

As a high-tech enterprise founded in 2018 by top epigenetic experts, Epiprobe focuses on the molecular diagnosis of cancer DNA methylation and precision theranostics industry. With a profound technology basis, we aim to lead the era of new products to nip cancer in the bud!

Based on Epiprobe core team’s long-term research, development and transformation in the field of DNA methylation with the cutting-edge innovations, combined with the unique DNA methylation targets of cancers, we use a unique multivariate algorithm combining big data and artificial intelligence technology to independently develop an exclusive patent-protected liquid biopsy technology.

  • 87+

    Cooperating Hospitals

  • 70000+

    Double-blind Verified Clinical Samples

  • 55

    Domestic and International patents

  • 25+

    Cancer Types

more >>
TAGMe

Worldwide Exclusive: Tumor Aligned General Methylated Epiprobe

More
  • Build a cancer-free world

    Vision

    Build a cancer-free world

  • Convince with products

    Value

    Convince with products

  • Keep everyone away from cancer

    Mission

    Keep everyone away from cancer

logo

application

Covering the whole process of cancer theranostics

news

Latest news of Epiprobe

news01

Epiprobe’s Three Cancer Methylation ...

On May 8, 2022, Epiprobe announced that its independently developed three cancer gene methylation detection...

Fudan University Research Team Targets Another ...

On July 6, 2022, the research team led by Dr. Yu Wenqiang at the Resear...
more >>

Epiprobe company won the title of “Specia...

Recently, Shanghai Municipal Commission of Economy and Information Technology announced the list ...
more >>